If you could invest 100k in one American stock right now, which would you pick?
Millennials are finally getting to the age of buying houses, 2000's houses are needing TLC now, and flippers are shifting into high gear.
This fucker's going to 200.
>Implying millenials will buy houses.
>Implying they are not realising that renting is better nowadays.
Either way, the places are getting built and people are living in them. Millennials are now 'forming households' at a record pace never seen in the US, even since the 50s.
It's your choice to throw your money away on rent.
Or Google if I wanted to play it safe.
Google is going to be the biggest most powerful company on Earth if they stay on the same track. RIG just seems like a good oil play, oil should do well under Trump.
Lol, this isn't a jack up the generic drug price scheme. It's a company with a recently approved drug, a potential mega-blockbuster that will start out treating life threatening orphan conditions, and a unique high-throughput method of discovering GPCR targeting drugs. Most blockbusters drugs target GPCR.
You'd guys better screencap this, this is the one time you've been given real investment advice. This stock will surpass a 50 billion market cap within 5 years. I'll post a thread here then to remind you.
the dip down to 233-234 is a great
buy opportunity; we are going to be bombing a lot of things. NOC is undervalued in the LMT/RTN/NOC/BAE set.
it's just the orange properties on monopoly desu
One of these (my portfolio) :
If I was to chose only one, and was after value then I would chose WPC, if I was after income, probably NRZ or MAIN, if I was after growth, probably HTGC...
Might be a year early on the name desu. I wouldn't be buying til it fills that gap ~57 and only starting to leg in there.. But this is definitely a 2018 story with data center growth, early 5G launch, expanding AI applications, ADAS growth etc etc.
Their management seems too unfocused to me. Yes GPCRs are an interesting therapeutic pathway, but making agonists/antagonists with predictable downtstream signaling to these receptors isn't as easy you make it sound. There have been plenty of synthetic cannabinoids for example which bind to the CB1 GPCR but had significant toxicities. We are talking about a class of transmembrane protein domains where each target may have several compounds that act on it.